- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00608842
Phase 2 Study for the Treatment of Superficial Lipomas
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Gary D. Monheit, M.D.
-
-
California
-
San Diego, California, United States, 92123
- Stacy R. Smith
-
-
Michigan
-
Warren, Michigan, United States, 48088
- Steven Grekin, D.O.
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
- Joel Schlessinger, M.D.
-
-
New Jersey
-
Westwood, New Jersey, United States, 07675
- David J. Goldberg, M.D.
-
-
New York
-
New York, New York, United States, 10021
- Neil S. Sadick, M.D.
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
- Michael H. Gold, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
One or more lipomas, based on clinical and histological diagnosis, which are accessible for treatment and assessment, are quantifiable along at least 2 perpendicular diameters, and have the following characteristics:
- History of slow growth followed by dormancy, and stable for at least 6 months
- Greatest length multiplied by greatest perpendicular width between 1 and 16 cm², inclusive
- Discrete, oval to rounded in shape, not hard or attached to underlying tissue
- Without changes in overlying skin (ie, inflammation, pain or tenderness, hyperpigmentation)
- Located on the trunk, arms, legs, or neck
- Signed informed consent.
Exclusion Criteria:
- Absence of significant medical conditions that could affect safety
- History of surgical or deoxycholate treatment for lipomas
- Treatment with an investigational agent within 30 days before ATX-101 treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deoxycholic Acid 1%
Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
|
Administered via intralipomal injection.
Other Names:
|
Experimental: Deoxycholic Acid 2%
Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
|
Administered via intralipomal injection.
Other Names:
|
Experimental: Deoxycholic Acid 4%
Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
|
Administered via intralipomal injection.
Other Names:
|
Placebo Comparator: Placebo
Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
|
Matching vehicle placebo administered via intralipomal injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 24 weeks
|
Severity of AEs was determined using the following scale: Mild: The participant was aware of a sign or symptom, but it was easily tolerated; Moderate: Discomfort or interference with usual activity; Severe: Incapacitating, with inability to engage in usual activity. The investigator determined the relationship of each AE to the administration of study material by answering the question: "Was there a reasonable possibility that the event may have been caused by treatment with study material?" A serious AE was an event that constituted a significant medical hazard or side effect, regardless of the investigator's or sponsor's opinion regarding relatedness to study material. Serious AEs included any event that was fatal or life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other significant medical hazard. |
Up to 24 weeks
|
Number of Participants With Newly Occurring or Worsening Biochemistry/Hematology/Urinalysis Abnormalities
Time Frame: 24 weeks
|
An abnormality is defined as a value outside the limits of the expanded normal range/notable range.
|
24 weeks
|
Number of Participants With Clinically Significant Changes in Vital Signs or Weight
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
|
Number of Participants With Positive Histopathology Results at Screening
Time Frame: Screening (prior to randomization)
|
A needle core tissue sample biopsy was performed at screening for all treated lipomas.
|
Screening (prior to randomization)
|
Number of Participants With Positive Histopathology Results at Week 20
Time Frame: Week 20
|
After the completion of all tests and procedures scheduled for week 20, participants with treated lipomas that remained palpable could have their treated lipomas excised.
|
Week 20
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Complete Clearance or ≥ 75% Clearance
Time Frame: Baseline and week 20 (8 weeks after last dose)
|
At randomization 1 to 3 lipomas were selected for treatment. Lipomas were measured in 3 dimensions (longest length, perpendicular width, and height if possible) using digital calipers. Complete clearance indicates target lipoma(s) not present or detectable, and ≥ 75% clearance is defined as a ≥ 75% reduction from baseline in the area of target lipoma(s). For participants with > 1 target lipoma, the total area of all target lipomas was used in the calculation of response. |
Baseline and week 20 (8 weeks after last dose)
|
Percent Change From Baseline in the Sum of the Areas of All Treated Lipomas
Time Frame: Baseline and week 12 (last treatment session), week 16 (4 weeks after last treatment), and week 20 (8 weeks after last treatment)
|
Percent change from baseline was calculated as the baseline total lipoma area - postbaseline total lipoma area / baseline total lipoma area * 100.
A positive change indicates a reduction in size.
|
Baseline and week 12 (last treatment session), week 16 (4 weeks after last treatment), and week 20 (8 weeks after last treatment)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Patricia S. Walker, M.D., Ph.D., Kythera Biopharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATX-101-07-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipoma
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustUnknownLipoma of Spinal CordUnited Kingdom
-
Universidade Metropolitana de SantosRecruiting
-
Zachary GerutAdvance Biofactures CorporationCompleted
-
Kythera BiopharmaceuticalsCompleted
-
Suez Canal UniversityCompleted
-
Gerut, Zachary, M.D.Advance Biofactures CorporationCompleted
-
Ruhr University of BochumCompletedSoft Tissue Sarcoma | Tumor | LipomaGermany
-
Pennington Biomedical Research CenterLipotheraCompleted
-
Yonsei UniversityCompletedVesico-Ureteral Reflux | Filum Terminale LipomaKorea, Republic of
-
University of MichiganAmryt PharmaEnrolling by invitationLipomatosis, Multiple SymmetricalUnited States
Clinical Trials on Deoxycholic Acid Injection
-
Kythera BiopharmaceuticalsBayerCompletedModerate or Severe Submental FullnessGermany, France, Belgium, Spain, United Kingdom
-
Kythera BiopharmaceuticalsCompletedPhase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)Moderate or Severe Submental FullnessUnited Kingdom, Canada, Australia
-
AllerganCompleted
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States, Canada
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States, Canada
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessAustralia, Canada, United Kingdom
-
Kythera BiopharmaceuticalsBayerCompletedModerate or Severe Submental FullnessBelgium, France, Germany, Italy, Spain, United Kingdom
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States